Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;76(5):525-534.
doi: 10.1055/s-0042-105871.

Metronomic Chemotherapy for Metastatic Breast Cancer - a Systematic Review of the Literature

M Banys-Paluchowski  1 , F Schütz  2 , E Ruckhäberle  3 , N Krawczyk  3 , T Fehm  3
Affiliations
Review

Metronomic Chemotherapy for Metastatic Breast Cancer - a Systematic Review of the Literature

M Banys-Paluchowski et al. Geburtshilfe Frauenheilkd. 2016 May.

Abstract
in English, German

Conventional chemotherapy is generally administered in high doses followed by a treatment-free period to give the body needful time to recover. This "maximum tolerated dose" approach results in high response rates. However, long periods between therapy cycles can lead to development of resistance mechanisms and consequently disease progression. One of the most interesting alternative strategies is metronomic chemotherapy. This concept relies on the continuous administration of chemotherapy at low doses and aims at targeting endothelial cells in the tumor bed as well. Recently, metronomic chemotherapy has been incorporated into the recommendations issued by the German AGO expert panel (www.ago-online.de). A systematic review of PubMed/Medline, ClinicalTrials.gov, the European Clinical Trials Database (EudraCT) and the Cochrane Database was conducted. In the present review, we discuss the current evidence on metronomic chemotherapy in metastatic breast cancer.

Die herkömmliche Chemotherapie wird üblicherweise in hohen Dosen verabreicht, gefolgt von einer behandlungsfreien Periode, die dem Körper die nötige Erholungszeit gibt. Dieser Ansatz, bei welchem dem Patienten die „maximal verträgliche Dosis“ verabreicht wird, ist mit hohen Ansprechraten verbunden. Die langen Abstände zwischen den einzelnen Therapiezyklen können jedoch die Entwicklung von Resistenzmechanismen begünstigen und folglich zu einem Fortschreiten der Erkrankung führen. Die metronomische Chemotherapie stellt daher eine interessante Alternative dar. Das Konzept beruht auf der kontinuierlichen Verabreichung eines niedrig dosierten Chemotherapeutikums und zielt auch auf die Endothelzellen im Tumorbett ab. Vor Kurzem wurde die metronomische Chemotherapie in die vom Expertengremium der AGO herausgegebenen Empfehlungen aufgenommen (www.ago-online.de). Es wurde eine systematische Recherche in PubMed/Medline, ClinicalTrials.gov, European Clinical Trials Database (EudraCT) sowie Cochrane Database durchgeführt. In der hier vorgestellten Literaturübersicht werden die aktuellen Erkenntnisse über die metronomische Chemotherapie bei der Behandlung von metastasierendem Brustkrebs diskutiert.

Keywords: breast cancer; metronomic chemotherapy; survival; systematic review; toxicity.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors declare that there are no conflicts of interest.

References

    1. Romiti A, Cox M C, Sarcina I. et al.Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol. 2013;72:13–33. - PubMed
    1. Klement G, Baruchel S, Rak J. et al.Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15–R24. - PMC - PubMed
    1. Browder T, Butterfield C E, Kraling B M. et al.Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878–1886. - PubMed
    1. Sparano J A, Wang M, Martino S. et al.Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663–1671. - PMC - PubMed
    1. Ghiringhelli F, Menard C, Puig P E. et al.Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–648. - PMC - PubMed